NovMetaPharma Co (XKRX:229500) Beginning Cash Position : ₩542.21 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co Beginning Cash Position?

NovMetaPharma Co's Beginning Cash Position for the quarter that ended in Dec. 2023 was ₩542.21 Mil.

NovMetaPharma Co's quarterly Beginning Cash Position declined from Dec. 2021 (₩2,487.32 Mil) to Dec. 2022 (₩1,904.32 Mil) and declined from Dec. 2022 (₩1,904.32 Mil) to Dec. 2023 (₩542.21 Mil).

NovMetaPharma Co's annual Beginning Cash Position declined from Dec. 2021 (₩2,487.32 Mil) to Dec. 2022 (₩1,904.32 Mil) and declined from Dec. 2022 (₩1,904.32 Mil) to Dec. 2023 (₩542.21 Mil).

NovMetaPharma Co Beginning Cash Position Historical Data

The historical data trend for NovMetaPharma Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovMetaPharma Co Beginning Cash Position Chart

NovMetaPharma Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

1,357.33

581.25

2,487.32

1,904.32

542.21

NovMetaPharma Co Semi-Annual Data
	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Beginning Cash Position	Get a 7-Day Free Trial				1,357.33	581.25	2,487.32	1,904.32	542.21

NovMetaPharma Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

NovMetaPharma Co Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of NovMetaPharma Co's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

NovMetaPharma Co (XKRX:229500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » Beginning Cash Position

Traded in Other Exchanges

N/A

Address

727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR

Website

http://www.novmeta.com

NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.

NovMetaPharma Co (XKRX:229500) Headlines

No Headlines